

November 27, 2006

Encision Named Stock of the Month by Investor Newsletter

Boulder, Colorado, November 27, 2006 -- Encision Inc. (Amex: ECI), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, announced that it has been selected as "Company of The Month" by *The Bowser Report* for its November 2006 stock report newsletter.

"We are delighted to be the featured stock in the November issue of *The Bowser Report* which was recognized as one of the top ten investment letters in 2005 by the Hulbert Financial Digest," said Jack Serino, President & CEO of Encision.

Authored by R. Max Bowser, the 30-year-old newsletter published in Newport News, Virginia uses fundamental analysis to select and recommend stocks to its subscriber base. Companies featured in the 10-page newsletter do not pay for the research and coverage and do not edit the newsletter's recommendations. The monthly newsletter recommends stocks at \$3.00 a share or less on the NYSE, NASDAQ and AMEX. One company is highlighted in each issue as "Company of the Month".

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase revenues through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.

CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com